- Home
- LCFY vs ALZN Comparison
LCFY vs ALZN Comparison
Compare LCFY & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- ALZN
- Stock Information
- Founded
- LCFY 2009
- ALZN 2016
- Country
- LCFY Australia
- ALZN United States
- Employees
- LCFY N/A
- ALZN N/A
- Industry
- LCFY
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- LCFY
- ALZN Health Care
- Exchange
- LCFY Nasdaq
- ALZN Nasdaq
- Market Cap
- LCFY 7.3M
- ALZN 7.0M
- IPO Year
- LCFY 2022
- ALZN 2021
- Fundamental
- Price
- LCFY $6.25
- ALZN $1.37
- Analyst Decision
- LCFY
- ALZN Strong Buy
- Analyst Count
- LCFY 0
- ALZN 1
- Target Price
- LCFY N/A
- ALZN $35.00
- AVG Volume (30 Days)
- LCFY 19.2K
- ALZN 128.2K
- Earning Date
- LCFY 11-12-2024
- ALZN 12-13-2024
- Dividend Yield
- LCFY N/A
- ALZN N/A
- EPS Growth
- LCFY N/A
- ALZN N/A
- EPS
- LCFY N/A
- ALZN N/A
- Revenue
- LCFY $3,169,582.00
- ALZN N/A
- Revenue This Year
- LCFY N/A
- ALZN N/A
- Revenue Next Year
- LCFY N/A
- ALZN N/A
- P/E Ratio
- LCFY N/A
- ALZN N/A
- Revenue Growth
- LCFY N/A
- ALZN N/A
- 52 Week Low
- LCFY $2.20
- ALZN $1.40
- 52 Week High
- LCFY $11.23
- ALZN $19.20
- Technical
- Relative Strength Index (RSI)
- LCFY 63.67
- ALZN 38.66
- Support Level
- LCFY $5.54
- ALZN $1.43
- Resistance Level
- LCFY $7.99
- ALZN $1.59
- Average True Range (ATR)
- LCFY 0.39
- ALZN 0.09
- MACD
- LCFY 0.17
- ALZN 0.00
- Stochastic Oscillator
- LCFY 61.62
- ALZN 15.38
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.